




Searching News Database: Neovasc
HSMN NewsFeed - 21 Oct 2022
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA(R) (aflibercept) Injection
HSMN NewsFeed - 18 Feb 2020
LumiThera to Expand Research into Diabetic Retinopathy for Valeda(R) Light Delivery System
LumiThera to Expand Research into Diabetic Retinopathy for Valeda(R) Light Delivery System
HSMN NewsFeed - 2 Dec 2019
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
Kodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors
HSMN NewsFeed - 11 Dec 2018
Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer(TM) as Published in JACC
Neovasc Announces Positive 12-year Follow-up Data for Neovasc Reducer(TM) as Published in JACC
HSMN NewsFeed - 13 Sep 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy
HSMN NewsFeed - 17 Aug 2018
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
FDA Approves EYLEA(R) (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
HSMN NewsFeed - 20 Jun 2018
Neovasc Announces First Implant of a Neovasc Reducer(TM) in a U.S. Patient
Neovasc Announces First Implant of a Neovasc Reducer(TM) in a U.S. Patient
HSMN NewsFeed - 11 Jun 2018
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update
HSMN NewsFeed - 25 May 2018
Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer
Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer
HSMN NewsFeed - 3 Jan 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating Officer
HSMN NewsFeed - 2 Dec 2016
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities
HSMN NewsFeed - 22 Nov 2016
Allergan Receives FDA Clearance for the XEN(R) Gel Stent, a New Surgical Treatment for Refractory Glaucoma
Allergan Receives FDA Clearance for the XEN(R) Gel Stent, a New Surgical Treatment for Refractory Glaucoma
HSMN NewsFeed - 11 Nov 2016
Sofregen Medical Acquires SERI(R) Surgical Scaffold Product Line from Allergan
Sofregen Medical Acquires SERI(R) Surgical Scaffold Product Line from Allergan
HSMN NewsFeed - 4 May 2016
Notal Vision Announces Appointment of Quinton Oswald as Chief Executive Officer
Notal Vision Announces Appointment of Quinton Oswald as Chief Executive Officer
HSMN NewsFeed - 11 Aug 2014
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
EYLEA(R) (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
HSMN NewsFeed - 8 May 2014
Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs
Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical Affairs
HSMN NewsFeed - 3 Feb 2014
Neovasc Inc. Announces Successful First Human Implant of Tiara(TM) Transcatheter Mitral Valve
Neovasc Inc. Announces Successful First Human Implant of Tiara(TM) Transcatheter Mitral Valve
HSMN NewsFeed - 14 May 2012
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of Wet-AMD
HSMN NewsFeed - 5 Apr 2012
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP(R) (aflibercept)
HSMN NewsFeed - 19 Mar 2012
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
QLT Receives Orphan Drug Designation for Visudyne for Treatment of Central Serous Chorioretinopathy
HSMN NewsFeed - 18 Apr 2011
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
HSMN NewsFeed - 8 Apr 2011
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
HSMN NewsFeed - 9 Feb 2010
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
HSMN NewsFeed - 6 Oct 2009
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech
HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
HSMN NewsFeed - 30 Apr 2009
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
HSMN NewsFeed - 7 Apr 2009
TransMolecular Appoints Robert Radie President and Chief Executive Officer
TransMolecular Appoints Robert Radie President and Chief Executive Officer
HSMN NewsFeed - 4 Feb 2009
Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
HSMN NewsFeed - 22 Dec 2008
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
TransMolecular Receives Orphan Drug Designation for 131I-TM601 for the Treatment of Melanoma
HSMN NewsFeed - 11 Jul 2008
Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration
Alcon Terminates the Development of Anecortave Acetate in Age-Related Macular Degeneration
HSMN NewsFeed - 2 Jul 2008
Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
HSMN NewsFeed - 28 Mar 2008
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
HSMN NewsFeed - 28 Mar 2008
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
HSMN NewsFeed - 23 Aug 2007
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
HSMN NewsFeed - 6 Aug 2007
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
HSMN NewsFeed - 18 Jun 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
HSMN NewsFeed - 20 Dec 2006
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
HSMN NewsFeed - 18 Oct 2006
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases
HSMN NewsFeed - 26 Sep 2006
Pfizer Expands Research Commitment to Ophthalmology Through Licensing Agreement With Quark Biotech
Pfizer Expands Research Commitment to Ophthalmology Through Licensing Agreement With Quark Biotech
HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
HSMN NewsFeed - 30 Jun 2006
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration
HSMN NewsFeed - 26 Jun 2006
Lumenis Invests in Exclusive, Worldwide License for New Ophthalmic Technology
Lumenis Invests in Exclusive, Worldwide License for New Ophthalmic Technology
HSMN NewsFeed - 8 May 2006
Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
Athenagen Announces the Appointment of John Donovan as Chief Financial Officer
HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Additional items found! 145

Members Archive contains
145 additional stories matching:
Neovasc
(Password required)
Neovasc
(Password required)